A Survey of Serum Bactericidal Antibodies against Neisseria meningitidis Serogroups A, C, W and Y in Adolescents and Adults in the Republic of Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: This descriptive epidemiological study aimed to assess the prevalence of serum bactericidal antibodies against Neisseria meningitidis serogroups A, C, W and Y in adolescents and adults in the Republic of Korea. Materials and Methods: In total, 987 subjects aged 11-55 years from five geographical regions of Korea were included in the study. Human serum bactericidal assay (hSBA) was used to measure hSBA titres for serogroups A, C, W and Y. Percentages of subjects with hSBA titres ≥4 and ≥8, geometric mean titres (GMTs), and associated 95% confidence intervals (CIs), were estimated. Analysis was performed for the entire study population and stratified by age group or region. No statistical hypotheses were tested. Results: The highest percentage of subjects with hSBA titres ≥8 was observed for serogroup W (74%), was similar for serogroups C (34%) and Y (36%), and was lowest for serogroup A (9%). The percentages of subjects with hSBA titres ≥4 were similar to those with hSBA titres ≥8 for all serogroups. GMTs were 2.56 μg/mL (serogroup A), 5.14 μg/mL (serogroup C), 22.63 μg/mL (serogroup W) and 5.28 μg/mL (serogroup Y). Similar trends in GMTs across serogroups were seen for individual regions and age groups. The highest GMTs for serogroups A, W and Y were recorded in the >19-29 years group, and for serogroup C in the >49-55 years group. Across all regions, GMTs were very similar for serogroups A, C and Y, while more variation was seen for serogroup W. Conclusion: In the Korean population, among Neisseria meningitidis serogroups A, C, W and Y, serum bactericidal antibodies were most prevalent against serogroup W and least prevalent against serogroup A. These trends were maintained across age groups and regions. The highest GMTs for serogroups A, W and Y were observed in the >19-29 years group. The reasons behind the observed differences in prevalence of bactericidal antibodies against the serogroups are currently not understood, although carriage and cross-reactivity of the assay may be important influences.
Abstract
Background: This descriptive epidemiological study aimed to assess the prevalence of serum bactericidal antibodies against Neisseria meningitidis serogroups A, C, W and Y in adolescents and adults in the Republic of Korea. Materials and Methods: In total, 987 subjects aged 11-55 years from five geographical regions of Korea were included in the study. Human serum bactericidal assay (hSBA) was used to measure hSBA titres for serogroups A, C, W and Y. Percentages of subjects with hSBA titres ≥4 and ≥8, geometric mean titres (GMTs), and associated 95% confidence intervals (CIs), were estimated. Analysis was performed for the entire study population and stratified by age group or region. No statistical hypotheses were tested. Results: The highest percentage of subjects with hSBA titres ≥8 was observed for serogroup W (74%), was similar for serogroups C (34%) and Y (36%), and was lowest for serogroup A (9%). The percentages of subjects with hSBA titres ≥4 were similar to those with hSBA titres ≥8 for all serogroups. GMTs were 2.56 μg/mL (serogroup A), 5.14 μg/mL (serogroup C), 22.63 μg/mL (serogroup W) and 5.28 μg/mL (serogroup Y). Similar trends in GMTs across serogroups were seen for individual regions and age groups. The highest GMTs for serogroups A, W and Y were recorded in the >19-29 years group, and for serogroup C in the >49-55 years group. Across all regions, GMTs were very similar for serogroups A, C and Y, while more variation was seen for serogroup W. Conclusion: In the Korean population, among Neisseria meningitidis serogroups A, C, W and Y, serum bactericidal antibodies were most prevalent against serogroup W and least prevalent against serogroup A. These trends were maintained across age groups and regions. The highest GMTs for serogroups A, W and Y were observed in the >19-29 years group. The reasons behind the observed differences in prevalence of bactericidal antibodies against the serogroups are currently not understood, although carriage and cross-reactivity of the assay may be important influences.
참고문헌 (30)
- Khatami A, "The epidemiology of meningococcal disease and the impact of vaccines", Expert Rev Vaccines, 9, pp.285~298 (2010)
- Jafri RZ, "Global epidemiology of invasive meningococcal disease. Global epidemiology of invasive meningococcal disease", Popul Health Metr, 11, pp.17~ (2013)
- Vyse A, "The burden and impact of severe and long-term sequelae of meningococcal disease", Expert Rev Anti Infect Ther, 11, pp.597~604 (2013)
- Halperin SA, "The changing and dynamic epidemiology of meningococcal disease", Vaccine, 30(Suppl 2), pp.B26~B36 (2012)
- Harrison LH, "Global epidemiology of meningococcal disease", Vaccine, 24(Suppl 2), pp.B51~B63 (2009)
- Vyse A, "Meningococcal disease in Asia: an under-recognized public health burden", Epidemiol Infect, 139, pp.967~985 (2011)
- 김종현, "Infectious diseases in children and adolescents in the Republic of Korea; Past & recent status", Korean Journal of Pediatrics, 54(12), pp.489~500 (2011), 대한소아과학회
- Bae SM, "Serological and genetic characterization of meningococcal isolates in Korea", Jpn J Infect Dis, 61, pp.434~437 (2008)
- 이상오, "Commencement of the Meningococcal Vaccination for the Republic of Korea Army", Infection and Chemotherapy, 45(1), pp.113~115 (2013), 대한감염학회[DOI]
- Christensen H, "Meningococcal carriage by age: a systematic review and meta-analysis", Lancet Infect Dis, 10, pp.853~861 (2010)
- Areum Durey, "Carriage Rates and Serogroups of Neisseria meningitidis among Freshmen in a University Dormitory in Korea", Yonsei Medical Journal, 53(4), pp.742~747 (2012), 연세대학교의과대학[DOI]
- Park H, "Carrier rate, serogroup and vaccination effect of Neisseria meningitidis on army trainees in Korea", Chungbuk Med J, 5, pp.45~57 (1995)
- Kellerman SE, "Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease", J Infect Dis, 186, pp.40~48 (2002)
- Lee HJ, "Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (Men-ACWY-CRM) in healthy Korean adolescents and adults", Int J Infect Dis, 28, pp.204~210 (2014)
- Snape MD, "Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants:a randomized controlled trial", JAMA, 299, pp.173~184 (2008)
- "Statistical database"[URL]
- Goldschneider I, "Human immunity to the meningococcus. I. The role of humoral antibodies", J Exp Med, 129, pp.1307~1326 (1969)
- Alberer M, "Immunogenicity and safety of concomitant administration of a combined hepatitis A", B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults, 2015, pp.22, 105~114
- Arguedas A, "Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines", Vaccine, 28, pp.3171~3179 (2010)
- Jackson LA, "Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents", Clin Infect Dis, 49, pp.e1~e10 (2009)
- Kim SA, "An expanded age range for meningococcal meningitis:molecular diagnostic evidence from population-based surveillance in Asia", BMC Infect Dis, 12, pp.310~ (2012)
- Li J, "Prevalence of meningococcal meningitis in China from 2005 to 2010", Vaccine, 33, pp.1092~1097 (2015)
- Abad R, "Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America", Epidemiol Infect, 142, pp.2461~2470 (2014)
- Lingappa JR, "Serogroup W-135 meningococcal disease during the Hajj, 2000", Emerg Infect Dis, 9, pp.665~671 (2003)
- 심성훈, "A Case of Meningococcal Sepsis and Meningitis with Complement 7 Deficiency in a Military Trainee", Infection and Chemotherapy, 45(1), pp.94~98 (2013), 대한감염학회[DOI]
- Trotter CL, "Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009", Clin Vaccine Immunol, 19, pp.219~222 (2012)
- Pollard AJ, "Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America", Emerg Infect Dis, 10, pp.1812~1815 (2004)
- Trotter CL, "Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008", PloS one, 8, pp.e55486~ (2013)
- Ceyhan M, "Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005", Vaccine, 25, pp.7233~7237 (2007)